Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Elgan Pharma Ltd.
The study will assess the efficacy and safety of NTRA-2112 on intestinal malabsorption in preterm infants as compared to placebo
Age
0–0
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Male or female pre-term infant 26 and up to 32 weeks gestation. Gestational age matching (±2 weeks) between maternal dates and/or early antenatal ultrasound
2. Birth weight ≥ 500g
3. Singleton or twin birth
You may not be if
1\. Complete enteral feeding
Clareo Health | Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants
